Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

MERS-CoV seronegative and seropositive camels received a single intramuscular dose of ChAdOx1 MERS, a replication-deficient adenoviral vectored vaccine expressing MERS-CoV spike protein, with further groups receiving control vaccinations. Infectious camels with active naturally acquired MERS-CoV infection, were co-housed with the vaccinated camels at a ratio of 1:2 (infected:vaccinated); nasal discharge and virus titres were monitored for 14 days. Overall, the vaccination reduced virus shedding and nasal discharge (p = 0.0059 and p = 0.0274, respectively). Antibody responses in seropositive camels were enhancedby the vaccine; these camels had a higher average age than seronegative. Older seronegative camels responded more strongly to vaccination than younger animals; and neutralising antibodies were detected in nasal swabs. Further work is required to optimise vaccine regimens for younger seronegative camels.

Original publication

DOI

10.1038/s41598-019-52730-4

Type

Journal article

Journal

Scientific reports

Publication Date

08/11/2019

Volume

9

Addresses

Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. harbina2@ngha.med.sa.

Keywords

Animals, Adenoviridae, Zoonoses, Coronavirus Infections, Viral Vaccines, Antibodies, Viral, Vaccination, Disease Outbreaks, Antibodies, Neutralizing, Middle East Respiratory Syndrome Coronavirus, Camelus, COVID-19 Vaccines